The goal of this clinical trial is to compare the safety and effectiveness of Elranatamab versus Lenalidomide in participants with newly diagnosed multiple myeloma who have recently undergone autologous stem cell transplant.
This trial is currently open and accepting patients.
This study is being conducted in three different parts (or arms). The two arms in this study that are open for enrollment are Arms B and C. Arm A is no longer open for patient enrollment. In Arm B, participants will receive Lenalidomide as maintenance therapy, and in Arm C participants will receive Elranatamab as maintenance therapy.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 760 patients (estimated)View More
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message